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Three years of survival data are now available and the
impact of the model for end-stage liver disease (MELD)
allocation system is becoming clear. After a decline in
new registrants to the waiting list in 2002, the num-
ber increased to 10 856 new patients in 2004. Since the
implementation of MELD, the percentage of patients
who have been on the list for 1–2 years has declined
from 24% to 19%. There has been a shift upward in the
percentage of patients with higher MELD scores on the
waiting list.
An increasing percentage of adult living donor liver re-
cipients are over the age of 50 years; from 1% in 1997
to 51% in 2004. Parents donating to children (93% of
living donors in 1995), represented only 14% in 2004.
Long-term adjusted patient survival declined with in-
creasing recipient age in adults following either DDLT
or LDLT.
Cirrhosis caused by chronic hepatitis C virus (HCV) is
the leading indication for liver transplantation and is
Note on sources: The articles in this report are based on the ref-
erence tables in the 2005 OPTN/SRTR Annual Report, which are
not included in this publication. Many relevant data appear in the
figures included here; other tables from the Annual Report that
serve as the basis for this article include the following: Tables 1.5,
1.7, 1.8, 9.1–9.13 and 10.1–10.15. All of these tables may be found
online at http://www.ustransplant.org.
associated with reduced long-term survival in recipi-
ents with HCV compared to those without HCV, 68%
at 5 years compared to 76%.
Although the intestine waiting list has more than dou-
bled over the last decade, an increasing number of
centers now perform intestinal transplantation with
greater success.
Key words: Deceased donors, graft survival, intestine
transplantation, liver transplantation, liver-intestine
transplantation, living donors, MELD, organ donation,
patient survival, PELD, SRTR, waiting list, HCV
Introduction
The field of liver transplantation remains in constant evolu-
tion. This is essential for a specialty in which the number
of patients in need far exceeds the availability of organ re-
sources. Periodic changes in organ allocation policy and
innovative methods for expansion of the donor pool have
been utilized over the past decade to increase the supply
of livers available for the many patients in need. However,
the impact of these changes on liver transplant candidates
and recipients must be constantly assessed.
The most significant change in organ allocation policy
within the past decade has been the adoption of the
model for end-stage liver disease (MELD) and a compan-
ion system for children, the pediatric end-stage liver dis-
ease (PELD) score, as the method by which livers from
deceased donors are allocated to patients on the Organ
Procurement and Transplantation network (OPTN) waiting
list. Last year’s Report on the State of Transplantation was
the first one where the impact of the MELD/PELD system
could be evaluated (1). A marked decline in new registra-
tions to the (OPTN) waiting list was observed. However, an
insufficient amount of time had passed for the impact of
this policy change on waiting list and posttransplant mor-
tality to be fully evaluated. Three years of survival data are
now available and the impact of MELD on both waiting list
and posttransplant survival is becoming clear.
In an effort to expand the donor pool and reduce waiting
list mortality, livers from older donors have been increas-
ingly utilized over the past decade. However, several single
center studies have recently reported that the use of liv-
ers from older donors may reduce survival following liver
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transplantation (2,3). Some reports have suggested that
older donors reduce survival only in patients with chronic
hepatitis C virus (HCV) (4,5). The impact of donor age on
posttransplant liver survival has been carefully evaluated in
the present report.
Cirrhosis caused by chronic HCV is the leading indication
for liver transplantation and as the HCV epidemic contin-
ues to mature this trend is certain to increase (6). This is
of major concern, since the survival of HCV patients after
liver transplantation appears to be reduced compared to
patients without HCV (7). Several studies have attempted
to identify various pre- and posttransplant factors associ-
ated with reduced survival in these patients. Unfortunately,
many of these studies provide only limited information be-
cause they contain too few patients or were conducted
at single centers, with limited variables. In addition to the
tables in the Annual Report (AR), we have analyzed data
contained within the SRTR database to evaluate the im-
pact of maintenance immunosuppression and coexistent
hepatocellular carcinoma (HCC) on posttransplant survival
in patients with chronic HCV.
The field of intestinal transplantation also continues to
evolve. Both graft and patient survival were reported as
increasing in the 2004 AR (1). An increasing number of
centers now perform intestinal transplantation. The cur-
rent report summarizes the continuing improvements in
graft and patient survival experienced by recipients of an
intestine transplant.
The basic structure of this article, which includes the pre-
ceding highlights, starts with a discussion on the liver trans-
plant waiting list characteristics. It moves on to liver recipi-
ent characteristics, liver patient survival, liver graft survival
and posttransplant death rates. The liver section wraps up
with a discussion on chronic HCV. The chapter then dis-
cusses the state of intestine transplantation, in a similar
order as the liver section.
Unless otherwise noted, the statistics in this article are
drawn from the reference tables in the 2005 OPTN/SRTR
Annual Report. A companion article in this report, ‘An-
alytical Methods and Database Design: Implications for
Transplant Researchers, 2005’, explains the methods of
data collection, organization and analysis that serve as the
basis for this article (8). Additional detail on the meth-
ods of analysis employed herein may be found in the
reference tables themselves or in the technical notes of
the OPTN/SRTR Annual Report, both available online at
http://www.ustransplant.org.
Liver
Liver transplant waiting list characteristics
Patients on the active and inactive waiting list: The
number of new patients added to the liver transplant wait-



































Source: 2005 OPTN/SRTR Annual Report, Table 1.5.
Figure 1: New liver waiting list registrations, 1995–2004.
ing in 2001. In 2002, the number of new registrants de-
clined for the first time in over a decade, but then increased
in 2003 and 2004. In 2004, 10 856 new patients were
registered, a value still less than the peak value in 2001
(Figure 1). It is possible that this 1-year decline in new reg-
istrants to the liver transplant waiting list was secondary
to the anticipated change in liver allocation policy imple-
mented in early 2002; from a system which favored the
length of time a patient had been listed to the MELD or
PELD model where waiting time played only a minor role.
This removed the incentive to place patients on the liver
transplant waiting list before they actually required liver
transplantation.
Patients on the liver waiting list can either be active or in-
active. The number of active patients increased steadily
between 1995 and 2001 (Figure 2). In 2002, the number of
patients active on the list declined for the first time in over
a decade and has remained relatively stable since then,
numbering 12 744 at the end of 2004. Between the years
2000–2004, 79% of listed patients were active on the wait-
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Figure 2: Number of patients on the liver waiting list active
at year-end, 1995–2004.
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Source: 2005 OPTN/SRTR Annual Report, Table 9.1a.
Figure 3: Percentage of patients on the liver waiting list, ac-
tive at year-end, by age, 1995–2004.
category. The percentage of patients on the inactive list in-
creases with the length of time the patient has been listed.
In 2004, 13% of all inactive patients had been on the wait-
ing list for 1–2 years, while 74% had been on the waiting
list for 2 or more years.
Age: Pediatric patients continue to make up a smaller
proportion of the entire active liver waiting list (Figure 3).
Although the number of pediatric patients listed for liver
transplantation remained relatively stable between 1995
and 2004, the proportion of patients who were children
(defined as age <18 years) declined from 9% to 3% dur-
ing this time. This reflects the increased number of adults
added to the active waiting list. The age of patients on the
active list shifted upward between 1995 and 2004. In 1995,
44% of patients were at least 50 years of age. In 2004, pa-
tients in this age range accounted for 68% of patients on
the active liver waiting list.
Race and ethnicity: The racial and ethnic distribution of
patients on the liver waiting list has remained steady over
the past decade, except for a slight increase in the pro-
portion of Hispanic/Latinos. In 2004, most patients on the
active liver waiting list were white (72%), followed by His-
panics/Latinos (16%), African Americans (7%) and Asians
(5%). The peak year for nonresident aliens on the waiting
list was 1999, when this group accounted for 2% of pa-
tients. The percentage of nonresident aliens on the active
liver waiting list has since steadily declined. In 2004, the
waiting list comprised only 0.5% nonresident aliens.
Gender: There continues to be more males than females
waiting for liver transplantation and this gap has increased
slowly over the last decade. This is because more males
have been added to the waiting list than females. In 1995,
55% of the patients on the active waiting list were males.
In 2004, this increased to 60%.
ABO type: Approximately half of all patients on the liver
transplant waiting list have blood type O. Blood type A ac-
counts for just over one-third of patients, blood type B for
about 10%–11% and type AB 2%–2.5%. The distribution
of blood types for patients on the liver waiting list has re-
mained relatively stable over the past decade and is similar
to that observed for the general population.
Prior transplantation: Although the absolute number
of patients on the active waiting list who had a prior trans-
plant of any kind increased from 264 patients in 1995 to
382 in 2004, the percentage of listed patients with a prior
transplant declined from 6% to 3%, respectively. Similarly,
the percentage of patients on the active waiting list who
received a previous liver transplant declined from 5.3% in
1995 to 2.6% in 2004. Thus, the vast majority of patients on
the current liver waiting list who received a prior transplant,
had a prior liver transplant. However, this percentage has
declined over the past decade, from 95% in 1995 to 87%
in 2004. This suggests that either recipients of other organ
transplants are increasingly being listed for liver transplants
or that retransplantation for liver graft failure is being per-
formed less frequently.
Diagnosis: Cirrhosis caused by a noncholestatic chronic
liver disease has been the primary indication for placing
individuals on the active liver transplant waiting list during
the past decade and the proportion of active patients on
the waiting list with this diagnosis has been increasing.
In 1995, 65% of patients waiting for liver transplantation
had cirrhosis secondary to a noncholestatic liver disease. In
2004, this had increased to 72%. This represented a 204%
increase in the absolute number of patients on the waiting
list with this diagnosis. This was primarily driven by patients
with chronic HCV that now accounts for just under 40% of
listed patients. During this time period, the overall number
of patients active on the waiting list increased by 172%.
In comparison, the number of patients with a cholestatic
liver disease who were active on the waiting list grew by
only 87% during this time. In 2004, cholestatic liver dis-
ease, acute hepatic necrosis, biliary atresia and metabolic
liver disorders accounted for 11%, 45%, 1.7% and 1.5% of
patients on the active liver transplant waiting list, respec-
tively.
Time on waiting list: Time spent on the liver waiting list
over the past decade is illustrated in Figure 4. The range
of <90 days is important since the MELD/PELD score is
based upon a 3-month mortality risk. Overall, the percent-
age of patients active on the waiting list that have been
waiting for long periods of time has increased steadily be-
tween 1995 and 2004. In 1995, 28.0% of patients had been
on the list 90 days or less and 29.7% had been on the list
for more than 1 year. In 2001, the percentage of patients
who had been on the list less than 90 days declined to
12% and the percentage on the list for more than 1 year
had ballooned to 60%. Since the implementation of the
MELD/PELD system in 2002, the percentage of patients
who had been on the list for 1–2 years has declined from
24% to 19%. The percentage of patients now waiting for
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Source: 2005 OPTN/SRTR Annual Report, Table 9.1a.
Figure 4: Percentage of patients on the liver waiting list, ac-
tive at year-end, by waiting time, 1995–2004.
2 years or more appears to be reaching a steady state (45%
in 2004).
Status 1: During 2003 and 2004, 47% of patients listed
as Status 1 received a liver transplant within 7 days. Dur-
ing this time, 14% of patients remained listed as Status 1,
3% were downgraded to a MELD/PELD score, 10% were
inactivated, 10% died, 5% were considered too sick for
transplantation and 9% had recovered. Fifteen days after
the initial listing as Status 1, the percentage of patients
transplanted had increased to 52% and only 5% remained
listed as Status 1. Another 5% were downgraded to a
MELD/PELD score, 9% were inactivated, 12% had died,
5% were now considered too sick for transplantation and
11% had recovered.
MELD/PELD system: The MELD/PELD system was in-
troduced in early 2002 as a better way to prioritize patients
on the active liver waiting list. Since then there has been
a shift upward in the percentage of patients with higher
MELD scores. At the end of 2002, 44% of patients had a
MELD score of 6–10, this declined to 40% by 2004. Dur-
ing this same time, the percentage of patients with MELD
scores of 11–20 increased while the percentage of patients
with MELD scores over 20 remained stable. In contrast,
the distribution of PELD scores has remained very similar
since this system was implemented. In 2002, 66%, 12%,
3% and 0.4% of pediatric patients on the active waiting
list had PELD scores of less than 11, 11–20, 21–30 and
greater than 30, respectively. In 2004, these values were
64%, 13%, 2% and 0.5%, respectively.
The positive impact of MELD was recently demonstrated
(9). In this study patients with MELD scores above 18 had
an improved survival 1 year following liver transplantation
as opposed to remaining on the waiting list; and the sur-
vival advantage of liver transplantation increased with in-
creasing MELD score. In contrast, patients with MELD
scores less than 18 had a reduced survival 1 year fol-
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Source: 2005 OPTN/SRTR Annual Report, Table 9.2b.
Figure 5: Events at 30, 60 and 90 days after snapshot of liver
waiting list by MELD score, as of January 1, 2004.
the waiting list. Another way to evaluate the impact of
MELD is to review what happens to patients listed at
various MELD scores after various waiting time intervals
(i.e. 30, 60 and 90 days) from an arbitrary index date or
‘snapshot’. The date utilized for this snapshot analysis was
January 1, 2004. The results of this analysis are illustrated
in Figure 5.
For patients with a MELD score of less than 11 within 30
days of the snapshot, 94% remained within this MELD
range and 4% had an increase in their MELD score. Trans-
plantation and death, within 30 days of the snapshot, were
uncommon in patients with these very low MELD scores.
They occurred in only 0.6% and 0.3% of patients. After 60
days, 7% of patients had developed an increase in their
MELD scores, 1% had undergone liver transplantation and
0.6% had died. After 90 days, these values had increased
to 9%, 1.6% and 0.8%, respectively. Thus, over time, a
small but increasing percentage of patients with a MELD
score of less than 11 underwent liver transplantation or
died.
For patients with MELD scores of 11–20 at the snapshot,
90% remained within this MELD range after 30 days, 3%
had a lower MELD score, and 2% had a higher MELD
score. During this 30-day period, 2.1% of patients received
a liver transplant and 0.8% died. After 60 days, 6% had
a lower MELD score and 3% had a higher MELD score.
The percentage of patients who received a liver transplant
had increased to 4% and 2% of patients had died. After
90 days, 8% had a lower MELD score, 3% had a higher
score, 6% of patients had received a transplant and 2%
died.
For patients with a MELD score of 21–30 at the snapshot,
52% remained within this same MELD range after 30 days,
15% had a decline in MELD scores and 3% had an in-
crease in MELD values to greater than 30. During these 30
days, 19% underwent liver transplantation and 4% died.
After 60 days, 16% had a lower MELD score, 2% had a
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higher MELD score, 29% had received a transplant and 7%
died. After 90 days, 29% of patients continued to have a
stable MELD score, 15% had a lower score, 2% had a
higher score and the percentage that had undergone liver
transplantation or died increased to 35% and 10%, respec-
tively.
For patients with the highest MELD scores (greater than
30) at the snapshot, 11% were still alive and waiting for
transplants with this high MELD score 30 days later, 9%
had a decline in MELD scores, 36% had received a liver
transplant and 36% had died. After 60 days, only 13% of
patients remained on the waiting list at any MELD score,
40% had received a transplant and 42% died. After 90
days, only 10% of patients who had a MELD score greater
than 31 remained on the waiting list, 40% of patients had
received a transplant and 45% had died. Thus, nearly all
patients who achieved a MELD score greater than 30 either
received a liver transplant within the first 30 days of this
event or did not survive.
Hepatocellular carcinoma and other MELD exceptions:
A similar snapshot analysis was performed for patients
with HCC (Figure 6). For patients with HCC stage T1, 28%
received a liver transplant within 30 days of the snapshot
date; 43% and 50% had a transplant within 60 and 90 days,
respectively. During these same time intervals, 3%, 5%
and 5% of patients died while waiting for a liver transplant
30, 60 and 90 days after the snapshot. For patients with
HCC stage T2, 31% of patients received a liver transplant
within 30 days of the snapshot date; 42% and 53% of pa-
tients had undergone transplantation by 60 and 90 days,
respectively. During these same time intervals, 0.8% of
patients had died within 30 days, while 0.8% and 2.4% of
patients had died within 60 and 90 days, respectively. For
patients listed with an exception other than HCC, 1% died
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Source: 2005 OPTN/SRTR Annual Report, Table 9.2b.
Figure 6: Events after snapshot of waiting list for liver candi-

































Source: 2005 OPTN/SRTR Annual Report, Table 9.4b.
Figure 7: Number of living donor liver recipients, 1995–2004.
Liver transplant recipient characteristics
Number of transplants: The number of liver trans-
plants in the U.S. has risen incrementally over the past
decade. Part of this can be attributed to the increased use
of marginal donors and expanded criteria donors, includ-
ing donation after cardiac death. Another reason is the in-
creased utilization of living donors. The number of living
donor liver transplants (LDLT) increased steadily between
1995 and 2001, declined, and then stabilized in 2003–2004
(Figure 7). The decline in the number of recipients of LDLT
since 2002 likely reflects: the change in the allocation pol-
icy to the MELD system, which provides high priority for
patients with HCC; the results from a National Institute
of Health Conference on living donor liver transplantation,
which pointed out the limitations and complications asso-
ciated with LDLT (10); and the highly publicized deaths of
at least two donors in this country.
The MELD/PELD system was implemented in 2002 as a
way to better prioritize patients for liver transplantation.
In this system, worsening renal dysfunction is associated
with a marked increase in MELD/PELD score and signifi-
cantly increased priority for liver transplantation. As a re-
sult, many patients who have received liver transplants
since 2002 have some degree of renal insufficiency. Renal
dysfunction in liver transplant candidates can be secondary
to either type-I or type-II hepatorenal syndrome or intrinsic
renal dysfunction, which is most commonly secondary to
hypertension and/or diabetes mellitus. The increased in-
cidence of renal dysfunction in liver transplant recipients
has led to an increase in the number of patients undergo-
ing combined liver and renal transplantation. In 2001, prior
to the implementation of MELD/PELD, only 3% of liver
transplant recipients had a simultaneous renal transplant.
In 2004, combined liver and renal transplantation had in-
creased to 5% of all liver transplant recipients (Figure 8).
Although it is believed that a combined liver-kidney trans-
plant in this setting may improve survival, hard data demon-
strating this are lacking. Recipient survival in patients un-
dergoing combined renal and liver transplantation should
be evaluated in future studies.
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Source: 2005 OPTN/SRTR Annual Report, Tables 1.7 and 1.8.
Figure 8: Recipients of liver transplants and simultaneous
liver-kidney transplants by year, 1995–2004.
Age: The increase in the number of deceased donor liver
transplant (DDLT) recipients over the past decade has been
predominantly in the adult population. As a result, despite
a 17% increase in the absolute number of pediatric (age
<18 years) liver transplants performed, the proportion of
pediatric liver transplant recipients relative to the total num-
ber of liver transplant recipients has declined over the past
decade from 12% in 1995 to 9% in 2004.
There has been a significant increase in the number of
LDLT recipients during the past decade. However, as was
observed for DDLT, the majority of this increase has been
in the adult population. The number of pediatric LDLT re-
cipients has remained very stable during this decade. In
1995, all of the 54 LDLT recipients were in the pediatric
population. In 2004, virtually the same number of LDLT re-
cipients were children, which accounted for only 16% of
all LDLT recipients. Since the initiation of LDLT in adults, an
increasing percentage of adult living donor liver recipients
have been over the age of 50 years; from 1% in 1997 to
51% in 2004 (Figure 9).
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Figure 9: Age of living donor liver transplant recipients, 1995–
2004.
Gender, race, ethnicity and blood type: The percent-
age of males receiving a DDLT has slowly and gradually
increased over the past decade from 57% in 1995 to 66%
in 2004. This likely reflects the increasing prevalence of
chronic HCV, which is twice as common in males as in
females, as the major indication for undergoing liver trans-
plantation (11). The proportion of DDLT recipients that are
white has slowly and gradually declined from 76% in 1995
to 72% in 2004. During this time there have been compen-
satory increases in the percentage of African American re-
cipients (from 8% in 1995 to 10% in 2004) and Asian recipi-
ents (from 3.4% in 1995 to 4.8%in 2004). There have been
no obvious trends in the blood types of liver transplant re-
cipients during the past decade. Approximately 42% have
type O, 40% type A, 13% type B and about 5% blood type
AB.
Prior transplantation: The percentage of DDLT recip-
ients who received a previous transplant of any kind de-
clined from 11% in 1995 to 9% in 2004. The most common
type of previous transplant received by liver transplant re-
cipients is a previous liver transplant, accounting for over
90% of previous transplants in 2004. In 1995, 10% of liver
transplant recipients had received a prior liver transplant.
In 2004, this had declined to 8%.
Payor type: Private insurance carriers continue to fund
over half of all DDLTs performed in this country. How-
ever, the percentage of liver transplant recipients with pri-
vate insurance has declined from 63% in 1995 to 60% in
2004. The percentage of patients whose transplant was
funded through Medicaid has declined slightly during the
past decade; from 17.3% to 16.1%. These changes have
been offset by an increase in the number of liver trans-
plants funded though the federal Medicare system. This
increased from 12% in 1995 to 18% in 2004. This gradual
shift from private and state funding to the federal funding
of liver transplantation likely reflects a higher percentage
of patients undergoing liver transplantation with more ad-
vanced liver disease and who, therefore, must seek dis-
ability through the federal social security system prior to
transplantation.
Most of the LDLTs performed in the US over the past
decade were funded by private insurance carriers. In 2004,
73% of LDLT recipients had private insurance, 11% had
Medicaid and 10% of recipients were funded through the
Medicare system.
Nearly all DDLT recipients are U.S. residents and this has
increased to an even higher percentage during the past
decade, from 97% in 1995 to 99% in 2004. A similar trend
was observed for recipients of a LDLT.
Diagnosis: During the past decade there has been an in-
cremental and gradual rise in the percentage of recipients
who received a DDLT for malignant neoplasms, from 2% in
1995 to 7% in 2004. This rise has been particularly evident
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since 2002, and consistent with the implementation of the
MELD system, which provides higher priority for patients
with T1 or T2 HCC. In contrast, the proportion of recipi-
ents with cholestatic liver disease has declined over the
past decade from 15% to 9%, respectively. Over 60% of
liver transplant recipients had cirrhosis secondary to non-
cholestatic liver disease as the primary indication for trans-
plantation. In 2004, 41% of these patients had cirrhosis
secondary to chronic HCV (SRTR Analysis, May 2005). The
major indication for transplantation in recipients of a living
donor was also cirrhosis secondary to a non-cholestatic
liver disease. In 2004, this accounted for over half of all
living donor recipients. The percentage of living liver donor
recipients whose primary indication for transplantation was
a malignant neoplasm has fluctuated between 2% and 9%
between 1999 and 2004.
Hospitalization status: Over the past decade, the per-
centage of DDLT recipients who were hospitalized at the
time of their transplant declined from 26% in 1995 to only
16% in 2004. The percentage of recipients who were in an
intensive care unit increased from 21% in 1995 until peak-
ing at 27% in 2001. This coincided with the last year of
the previous allocation system when patients in the inten-
sive care unit received higher priority on the liver waiting
list. With the implementation of the MELD/PELD system
in 2002, the percentage of recipients in intensive care units
declined (Figure 10). The percentage of recipients who re-
ceived a liver transplant while on life support has declined,
as well, from 14% in 1995 to only 7% in 2004.
For recipients of a LDLT, the percentage of patients hos-
pitalized at the time of transplant has also declined during
the past decade. In 1995, all LDLT recipients were in the
pediatric age range and 26% were hospitalized. This de-
clined to 12% in 2004 and only 16% of recipients were in
the pediatric age range. The percentage of LDLT recipients
in intensive care units and on life support has also declined
during this time, from 17% and 15% in 1995 to 7% and
2% in 2004, respectively.
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Figure 10: Hospitalization status at transplant for deceased
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Source: 2005 OPTN/SRTR Annual Report, Table 9.4a.
Figure 11: Distribution of deceased donor liver recipients by
MELD score, 2002–2004.
MELD score: There are now 3 years of data available
to assess the effects of the MELD/PELD system. In 2002,
27% of DDLT recipients had a MELD score of less than 21
and 10% had a MELD score of greater than 30. In 2004,
the percentage of DDLT recipients with a MELD score of
less than 21 remained fairly stable while the percentage
of recipients with a MELD score greater than 30 increased
to 14% (Figure 11). One of the primary features of the
MELD system is that it provides a higher MELD score for
patients with HCC than they otherwise would have had,
based upon their liver and renal function alone. The per-
centage of DDLT recipients with HCC remained relatively
stable between 2002 and 2004, ranging between 14% and
17%. Another feature of MELD is that it allows exceptions
to be assigned and provides an elevated MELD for patients
with unique circumstances. Such exception proposals are
submitted to the respective regional review boards for a
vote before being applied. Recipients of a DDLT with an
exception increased slightly since implementation of the
MELD system, from 6% in 2002 to 8% in 2004.
In contrast to what has been observed with DDLT re-
cipients, the MELD scores for LDLT recipients have de-
clined since 2002. The percentage of LDLT recipients with
a MELD of less than 21 increased from 55% in 2002 to
70% in 2004. The percentage of LDLT recipients with HCC
has remained stable, ranging from 2.8% to 3.4% for 2002
to 2004.
Characteristics of living donors: The vast majority of
living donors are related to their recipients. However, as
the number of adult LDLT recipients has increased, so
has the percentage of unrelated donors. In 1995, when
all living donor recipients were in the pediatric age group,
only 2% of donors were unrelated to their recipients. The
percentage of unrelated donors has increased every year
since 1995, to 22% in 2004. Of the donors related to their
recipients, the majority are now donating to their adult
parents or siblings. This accounted for 14% and 19% of
all donors in 2004, respectively. Parents donating to their
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children, which accounted for 93% of living donors in 1995,
represented only 14% in 2004. This again represents the
increased utilization of living donors for adult recipients and
that parents of adult recipients are in many cases too old
to be considered viable living donors.
Immunosuppression: Induction immunosuppression.
The use of induction immunotherapy in liver transplanta-
tion is low when compared to that utilized for other organs.
In 1995, 15% of patients received induction with a mon-
oclonal antibody, either OKT3 or anti-thymocyte globulin
(ATG). In 2004, the use of these monoclonal antibodies for
induction had declined to only 0.6%. The use of thymoglob-
ulin has emerged in its place, along with interleukin recep-
tor antagonists (Zenepax and Simulect), in roughly equal
proportions.
Maintenance immunosuppression. The most common
agent utilized for maintenance immunosuppression during
the past decade has been tacrolimus. The percentage of
recipients discharged, following transplantation while on
this agent, has steadily increased from 48% in 1995 to
89% in 2004. The use of cyclosporin and its various forms,
including generic formulations of this calcineurin inhibitor,
has declined during the past decade from 47% in 1995 to
only 8% in 2004.
The use of an antimetabolite as a second maintenance im-
munosuppressive agent has increased from 42% to 58%
of liver transplant recipients. During this time mycopheno-
late mofetil (MMF) has become the primary antimetabo-
lite utilized in liver transplant recipients, largely replacing
azathioprine. In 1995, only 6% of liver transplant recipi-
ents were discharged with MMF. This increased to 56%
in 2004. Sirolimus was utilized as a maintenance immuno-
suppressive agent in 9%–10% of patients in 2000–2001,
shortly after this agent became available. However, the per-
centage of patients discharged on Sirolimus following liver
transplantation has declined to only 4%–5% between 2003
and 2004. The decline in Sirolimus usage after liver trans-
plantation may be related to recent studies, which have
suggested that this agent may be associated with a higher
incidence of portal vein thrombosis and poor wound heal-
ing (12). The use of corticosteroids at the time of discharge
in liver transplant recipients has declined from 88% in 1995
to 81% in 2004, reflecting a trend by some centers to either
rapidly taper off steroids or to perform liver transplantation
in a steroid-free environment.
Treatment of rejection. The incidence of antirejection treat-
ment within the first year following liver transplantation
has declined from 43% to 18% over the past decade (Fig-
ure 12). Steroids have been utilized for treatment of acute
rejection within the first year of transplantation in approxi-
mately 90% of liver transplant recipients and this has not
changed over the past decade. The use of various anti-
body preparations for treatment of acute rejection during































Source: 2005 OPTN/SRTR Annual Report, Tables 9.6i.
Figure 12: Incidence of acute antirejection treatment during
the first year following liver transplant, 1994–2003.
30% in 1995 to only 18% in 2004. OKT3 had been the an-
tibody preparation of choice in 1995. By 2004, thymoglob-
ulin and OKT3 were being utilized in a similar percentage
of patients for treatment of acute rejection.
Liver transplant patient survival
Deceased and living donor transplants: Patient sur-
vival, adjusted for recipient age, gender, race and diagnosis
at the time of deceased donor transplantation, was 93%
at 3 months, 87% at 1 year, 79% at 3 years and 73% at
5 years. For recipients of a LDLT, survival was 94%, 88%,
80% and 77%, respectively (Figure 13). Thus, patients who
had a LDLT appeared to have somewhat improved survival
after 5 years compared to patients who received a DDLT.
However, it is important to note that the vast majority of pa-
tients who received a LDLT who had enough data available
to calculate 5-year survival were in the pediatric population.
During the past decade there has been a small, gradual
increase in unadjusted patient survival 3 months following
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Source: 2005 OPTN/SRTR Annual Report, Tables 9.11a and 9.11b.
Transplant 
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Figure 13: Adjusted patient survival of deceased and living
donor liver recipients.
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in 2004. A similar upward trend in unadjusted patient sur-
vival was observed in patients who received a LDLT, from
87% in 1995 to 96% in 2004. At 1 year, patient survival was
slightly lower in recipients of a DDLT compared to LDLT,
at 87% versus 88%, respectively. Unadjusted patient sur-
vival remained higher for recipients of a LDLT compared to
the recipients of a DDLT after 3 (80.2% vs. 79.1%) and 5
years (77% vs. 73%).
Recipient demographics: Long-term, but not short-
term, adjusted patient survival declined with increasing re-
cipient age in adults following either a DDLT or LDLT (Fig-
ures 14 and 15). Adjusted patient survival was similar in
recipients regardless of age 3 months after either a DDLT
or LDLT. However, by 1 year a small but consistent step-
wise decline in adjusted patient survival was observed with
increasing age in adults and this decline widened at 3 and 5
years. Adjusted patient survival 5 years following a DDLT in
recipients aged 18–34 years was 78% compared to 64%
for those 65 years or older. This decline in survival with
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Source: 2005 OPTN/SRTR Annual Report, Table 9.11a.
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Figure 14: Adjusted patient survival of deceased donor liver
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Source: 2005 OPTN/SRTR Annual Report, Table 9.11b.
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Figure 15: Adjusted patient survival of living donor liver re-
cipients at various time intervals, by age.
a LDLT. Adjusted patient survival 1 year after a LDLT was
94% in patients aged 18–34 years and 75% in patients 65
years or older. At 5 years, adjusted survival in the recipi-
ents of a LDLT aged 18–34 years was 87% compared to
64% in those 65 years or older. No consistent relationship
between survival and age was observed in pediatric liver
transplant recipients who received either a LDLT or DDLT.
Adjusted patient survival at various time points was essen-
tially identical for males and females with a DDLT. After
5 years, survival was 73% for both. Survival was similar in
males and females who received a LDLT through 1 year.
Thereafter, the survival of female LDLT recipients tended
to be greater; 82% at 3 years and 79% at 5 years, com-
pared to 79% and 76% in males for the same lengths of
time.
Asians had the best survival following a DDLT at all time
points. After 5 years this was 77% compared to 73% for
whites, 74% for Hispanics and 65% in African Americans.
The survival of African Americans was consistently lower
than other racial/ethnic groups at all time points following
a DDLT. African Americans also had the lowest survival
following a LDLT. After 5 years, LDLT survival was 71%
compared to 81% in Asians, 77% in whites and 80% in
Hispanics.
Recipient disease: Adjusted patient survival at 3 months
was similar regardless of the etiology for liver transplanta-
tion in both DDLT and LDLT (>90%). The only exceptions
were those patients who received a DDLT for acute hepatic
necrosis (87%) and a LDLT for either a metabolic liver dis-
ease (81%) or acute hepatic necrosis (81%). After 1 year,
adjusted patient survival was similar for DDLT with regard
to diagnosis (>85%). At 5 years, the highest survival rates
were observed in recipients who received a DDLT for bil-
iary atresia (83%) and metabolic diseases (81%). The low-
est survival rates were observed in patients with acute
hepatic necrosis (70%) and malignant neoplasia (60%).
Similar trends exist for patients who received a LDLT. Af-
ter 5 years, the survival of patients who received a LDLT
for biliary atresia was 84%; survival was 87% for patients
with a cholestatic liver disease. The lowest survivals after
LDLTs were observed in patients with acute hepatic necro-
sis and malignant neoplasia at 71% and 58%, respectively
(Figure 16).
Effect of disease severity: Unadjusted patient survival
declined with worsening disease acuity, which was as-
sessed by the intensity of medical services provided at
the time of transplantation. In patients who received a
DDLT, the 3-month survival was 95% for patients not
hospitalized, 91% when hospitalized, 86% when in an
ICU and 80% when on life support. In patients who had
a LDLT, a similar relationship was observed. Survival at
3 months following a LDLT was 95% in patients not
hospitalized, 91% in those hospitalized, 81% in patients
in an ICU and 82% for patients when on life support.
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Deceased donors Living Donors
Source: 2005 OPTN/SRTR Annual Report, Tables 9.11a and 9.11b.
Figure 16: Adjusted patient survival of deceased and living


























Deceased Donors Living Donors
Source: 2005 OPTN/SRTR Annual Report, Tables 9.12 a and 9.12 b.
Figure 17: Unadjusted patient survival of deceased and living
donor liver recipients at 5 years after transplant, by hospital-
ization status at transplant.
The decline in survival with increasing disease acuity at
the time of either DDLT or LDLT was maintained after
1, 3 and 5 years. Survival at 5 years following a DDLT
was 75%, 70%, 68% and 62%, respectively. Similar re-
sults were observed for patients who received a LDLT
(Figure 17).
The recipients of DDLTs listed as Status 1 had a 3-month
survival of 86% compared to 81% for patients who re-
ceived a LDLT. This difference declined with time. Five
years later, survival for Status 1 patients following a DDLT
and LDLT was at 74% and 72%, respectively.
Because the MELD/PELD system was initiated in 2002,
only short-term survival data on a limited number of adults
are available at this time. Insufficient data exist to exam-
ine the effect of PELD on recipient survival. Overall patient
survival at 3 months was above 92% for recipients of a
DDLT or a LDLT in MELD groups except for those with a
MELD score above 30, where it was 88% for DDLT recipi-
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3 months 1 year
Source: 2005 OPTN/SRTR Annual Report, Tables 9.12a and 9.12b.
Figure 18: Unadjusted patient survival of deceased and living
donor liver recipients at 3 months and 1 year, by MELD score,
2002–2004.
score above 30 to get precise survival estimates. After 1
year, patient survival was over 84% for all MELD groups,
excepting those patients with a MELD score greater than
30. In these patients, 1-year DDLT survival had declined to
79%. Patients who underwent either a DDLT or LDLT for
HCC had a 1-year survival of over 89%. DDLT recipients
with an exception had similar 3-month and 1-year survival
(94% and 89%) as observed for other patients (Figure 18).
Donor age: Increasing donor age did not appear to af-
fect short-term survival but had a profoundly negative im-
pact on long-term survival following a DDLT (Figure 19).
After 3 months, unadjusted patient survival was greater
than 90% for recipients of livers obtained from all donor
age groups. In contrast, by 1-year survival had declined in
those recipients who received a liver from a donor over
50 years of age (85% for donors aged 50–64 years and
82% for donors over 65 years of age) compared to those
patients who received a liver from a younger donor (87%–
92%). The survival of recipients who received older donor
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Source: 2005 OPTN/SRTR Annual Report, Table 9.12a.
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Figure 19: Unadjusted patient survival of deceased donor
liver recipients at various time intervals, by donor age.




























Deceased Donor Living Donor
Source: 2005 OPTN/SRTR Annual Report, Tables 9.8a and 9.8b.
Transplant 
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Figure 20: Adjusted graft survival of deceased and living
donor liver recipients at various time intervals following
transplant.
difference became evident for donors down to 35 years
of age. After 5 years, the survival of DDLT patients with
donors less than 35 years of age was above 76%. In con-
trast, the 5-year survival for a 35–49-year-old donor was
72%, for donors aged 50–64 years survival was 68% and
for donors over 65 years of age survival was only 62%.
The effect of increased donor age on recipients of a LDLT
is unknown, primarily because very few individuals over 50
years of age become living donors (only 75 donors out of
664 living donations; 11% in 2002–2003).
Transplant factors: In 2004, the majority of livers from
deceased donors (74%) had a cold ischemia time of 10 h
or less. Of the remaining livers, cold ischemia times were
11–15 h for 10%, and over 16 h for 1% of donor livers.
Increasing cold ischemia time was not associated with a
decline in patient survival following a DDLT.
The vast majority of DDLTs (82%) and LDLTs (86%) per-
formed in 2002–2003 were done at transplant centers per-
forming at least 35 DDLTs and/or LDLTs yearly. No consis-
tent relationship was observed between transplant center
volume and either short-term or long-term survival follow-
ing liver transplantation. However, a recent report from the
National Institutes of Health sponsored Adult-to-adult liv-
ing donor liver transplant cohort study (A2ALL) has clearly
demonstrated that morbidity and graft mortality is signif-
icantly greater in the first 20 patients who undergo LDLT
when such a program is first initiated (13).
Liver transplant graft survival
Deceased and living donor transplants: Graft survival
adjusted for recipient age, gender, race and diagnosis at
the time of a DDLT was 89% at 3 months, 82% at 1 year,
73% at 3 years and 67% at 5 years. For recipients of a
LDLT, graft survival was similar; 88%, 82%, 73% and 69%,
respectively (Figure 20).
During the past decade there has been a gradual increase in
unadjusted graft survival 3 months after a DDLT, from 84%
in 1995 to 90% in 2004. A similar upward trend in unad-
justed graft survival was observed in LDLT recipients, from
81% in 1995 to 88% in 2004. Graft survival was similar in
recipients of a DDLT (82%, 73%, and 67%) as compared
to a LDLT (82%, 73%, and 70%) after 1, 3 and 5 years,
respectively.
Recipient demographics: Short-term graft survival ad-
justed for population characteristics at the time of de-
ceased donor liver transplantation was similar across all
age groups (greater than 84% survival) except for patients
less than 1 year of age where graft survival at 3 months
was 82%. Graft survival declined in all age groups over time
but this was greatest in those patients 65 years of age and
over. For all other age groups, adjusted graft survival fol-
lowing a DDLT was always greater than 72% at 3 years and
greater than 67% at 5 years. In patients over 65 years of
age, graft survival was 68% and 60% at 3 and 5 years, re-
spectively. For recipients of a LDLT, adjusted graft survival
was similar throughout all age groups without any apparent
relationship to patient age. Graft survival declined in all age
groups over time. However, as was observed for recipients
of a deceased donor graft, graft survival following a LDLT
declined to a greater extent in patients 65 years and older.
After 5 years, graft survival in patients 65 years and older
was 61% compared to greater than 66% for all other age
groups.
Adjusted graft survival was similar in both males and fe-
males following a DDLT. In contrast, long-term graft sur-
vival after 5 years was lower in males who received a LDLT
at 67% compared to 72% for females. With respect to
race, graft survival in African Americans was consistently
lower compared to that of other races for all time peri-
ods following either a DDLT or LDLT. Short-term adjusted
graft survival following a DDLT at 3 months was 87.8% in
African Americans compared to greater than 89.3% for all
other racial and ethnic groups. After 5 years, graft survival
in African Americans was 59% compared to greater than
67% for all other racial and ethnic groups. In LDLT recipi-
ents, adjusted graft survival was 81% and 57% in African
Americans compared to greater than 87% and greater than
69% for all other racial and ethnic groups at 3 months and
5 years, respectively.
Recipient disease: Adjusted graft survival at 3 months
was similar regardless of the etiology for liver transplanta-
tion in both DDLT and LDLT recipients (greater than 83%).
The only exceptions were in those patients who received
a DDLT for acute hepatic necrosis (82%) and LDLT for ei-
ther a malignant neoplasia (79%) or acute hepatic necrosis
(78%). After 1 year, adjusted graft survival was similar with
regard to diagnosis following DDLT (greater than 78%) ex-
cept in those patients who received a DDLT for acute hep-
atic necrosis (74%). At 5 years, the highest graft survival
rates were observed in recipients of DDLTs for metabolic
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diseases (75%). The lowest survival rates were observed in
patients with acute hepatic necrosis (63%), cirrhosis sec-
ondary to a noncholestatic disease (66%) and malignant
neoplasia (54%). After 5 years, graft survival was highest
for LDLT recipients with a diagnosis of either biliary atre-
sia (73%) or cholestatic liver disease (73%). The lowest
graft survival after LDLT were observed in patients with
metabolic diseases and malignant neoplasia, at 62% and
52%, respectively.
Unadjusted graft survival at all time points was markedly
reduced in patients who underwent retransplantation com-
pared to patients with just an initial transplant. This was
true for the recipients of either a DDLT or LDLT. At
3 months, graft survival of patients who underwent re-
transplantation with either a deceased or living donor graft
was 77% and 73%, respectively, compared to 90% and
88% for recipients of their initial graft. At 5 years, graft
survival following retransplantation was 50% and 54% for
recipients of deceased and living donor grafts, compared
to 69% and 70% for patients undergoing their initial liver
transplant, respectively.
Effect of disease severity: Unadjusted graft survival de-
clined with the intensity of medical care provided at the
time of transplantation. In patients who received a DDLT,
3-month graft survival was 92% for patients not hospital-
ized, 88% when hospitalized, 79% when in an ICU and
73% when on life support. In patients who received a LDLT,
a similar relationship was observed. Survival 3 months af-
ter a LDLT was 89% in patients not hospitalized, 89% in
those hospitalized, 71% for patients in an ICU and 68%
for patients when on life support. The decline in survival
associated with the intensity of medical care at the time
of either DDLTs or LDLTs was observed after 1, 3 and 5
years. Graft survival 5 years after a DDLT was 70%, 63%,
60% and 52% for each level of medical care provided, re-
spectively. Similar results were observed for patients who
received a LDLT.
Three-month graft survival in DDLT recipients, while listed
as Status 1, was 79% compared to 70% for patients who
received a LDLT. This difference declined with time. Five
years later, graft survival for Status 1 patients following a
DDLT or LDLT was 60% and 62%, respectively.
Since the MELD/PELD system was initiated in 2002, only
short-term graft survival data are available at this time. Graft
survival 3 months after a DDLT was greater than 88% in all
groups except for those with a MELD/PELD score over 30
(85% and 71%, respectively). After 1 year, graft survival
was greater than 79% for all MELD/PELD groups, again
except those patients with a MELD/PELD score higher
than 30 at the time of transplantation (76% and 64%, re-
spectively). Although a similar relationship was observed
in LDLT recipients, very few patients with a MELD/PELD
score greater than 30 underwent this procedure, so reliable
graft survival data for this group is not available. Patients
who received either a DDLT or LDLT for either stage T1 or
T2 HCC had a 1-year graft survival greater than 85%. Pa-
tients who underwent a DDLT with an exception had simi-
lar 3-month and 1-year graft survival (greater than 89% and
greater than 83%) as was observed for other patients.
Donor age: A parabolic relationship appears to exist with
respect to donor age and unadjusted short-term graft sur-
vival following a DDLT (Figure 21). At 3 months, graft sur-
vival was greater than 92% for recipients of livers obtained
from donors 11 to 34 years of age. Graft survival declined
stepwise with donor ages less than 11 years of age to only
79% for donors under 1 year of age. Graft survival at 3
months also declined with increasing donor age above 34
years to 84% for donors over 65 years of age. The decline in
graft survival with donors under 6 years old likely reflects an
increased risk of technical complications in smaller donor
livers (14). With an increase in time following liver trans-
plantation, graft survival in patients who received a younger
donor graft became similar to that observed for the 11–34-
year-old group. In contrast, graft survival in older donors
continued to decline with time. By 1 year, graft survival
had declined to 79% in those recipients who received a
liver from a donor 50 to 64 years of age and to 75% in re-
cipients of donors over 65 years of age. Graft survival con-
tinued to decline with time in those that received an older
donor graft; this difference was evident for donors down
to 35 years of age. After 5 years, graft survival following a
DDLT with donors less than 35 years of age was greater
than 69%. In contrast, 5-year graft survival for donors aged
35–49 years was 66%, for donors aged 50–64 years sur-
vival was 61% and for donors over 65 years of age graft
survival was only 54%.
Cold ischemia time: Unadjusted graft survival appeared
to decline with increasing duration of cold ischemia time.
When the deceased donor liver graft had less than 6 h
of cold ischemia time, graft survival 3 months after the
transplant was at 92%. Survival declined to 90% when
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Source: 2005 OPTN/SRTR Annual Report, Table 9.9a.
Figure 21: Unadjusted graft survival of deceased donor liver
recipients at various time intervals, by donor age.
American Journal of Transplantation 2006; 6 (Part 2): 1170–1187 1181
Shiffman et al.
11–15 h of cold ischemia time and 82% with 16–20 h of
cold ischemia time. Less than 1% of grafts had greater
than 21 h of ischemia time so graft survival data is likely
to be unreliable for this group. This trend of declining sur-
vival with increased duration of cold ischemia time was
observed at 1, 3 and 5 years following transplantation.
Pretransplant death rates
Crude death rates for patients on the liver transplant wait-
ing list have decreased consistently and considerably over
the past decade. For all patients on the waiting list, there
were 200 deaths per 1000 patient-years at risk (TPYAR) in
1995 and this declined to 126 deaths per TPYAR in 2004
(Figure 22).
Age: The highest age-specific waiting list death rates were
observed at the extremes of the age distribution. Candi-
dates less than 1 year of age consistently experienced the
highest death rates during the past 10 years. However, by
2004 there had been a 43% reduction in the death rate of
this age group, from 1044 to 591 deaths per TPYAR. The
second highest death rate was observed in patients above
65 years of age. However, the death rate in this age group
also declined by 41% between 1995 and 2004 from 296
to 174 deaths per TPYAR.
Demographic features: During the past decade, African
Americans have consistently had the highest death rate for
any of the racial and ethnic groups on the liver transplant
waiting list. In 2004, the death rate observed in African
Americans was 144 per TPYAR compared to 130 for His-
panics, 125 for whites and 90 for Asians. Asians have gen-
erally had the lowest waiting list death rates over the past
decade. Between 1995 and 2004, males have consistently
had a higher death rate while on the liver waiting list com-
pared to females. In 2004, the death rate for males was
131 deaths per TPYAR compared to 119 per TPYAR for fe-
males. No consistent relationship between blood type and
death rates has been observed during the past decade. In











































Source: 2005 OPTN/SRTR Annual Report, Table 9.3.
Figure 22: Unadjusted death rates per 1000 patient-years at









































Source: 2005 OPTN/SRTR Annual Report, Table 9.3.
Figure 23: Unadjusted death rates per 1000 patient-years at
risk for patients on the liver waiting list, by MELD Score 2002–
2004.
were observed in patients with blood type B. The highest
death rates, at 130 per TPYAR, occurred in patients with
blood type O.
Medical urgency: As expected, waiting list death rates
increased with increasing MELD/PELD scores at the time
of listing. However, death rates within each MELD group-
ing have consistently declined between 2002, when the
MELD/PELD system was first adopted, and 2004. During
2004, the death rate ranged from 45 deaths per TPYAR,
among patients with a MELD score between 6 and10, to
2993 deaths per TPYAR in patients listed with a MELD
score greater than 30 (Figure 23). Death rates also tended
to increase with increasing PELD scores; although, due to
small numbers, the PELD-specific death rates are much
more variable than their MELD counterparts. The death
rate for patients initially listed at Status 1 has also declined
stepwise over the past 10 years. In 1995, the death rate
for a Status 1 patient was 984 per TPYAR compared to 545
per TPYAR in 2004.
Posttransplant death rates
Recipient death rates during the first year following liver
transplantation have also decreased over the past 10 years
(Figure 24). This is similar to the trend observed in waiting
list death rates. The 1-year death rate following DDLTs in
1995 was 208 per TPYAR compared to 165 per TPYAR in
2003, the last year from which data is available to calculate
1-year survival. Similarly, the 1-year posttransplant death
rate also declined over the past decade in LDLT recipients.
In 1995, the 1-year posttransplant death rate for patients
who underwent a LDLT was 222 per TPYAR and this de-
clined to 136 per TPYAR in 2001. The death rate increased
to 171 per TPYAR in 2002 before declining again to 104
deaths per TPYAR in 2003. The reason behind the increase
in the 1-year posttransplant death rate during 2002 in pa-
tients who underwent LDLT is unclear at this time. Because
of limited data, it is not possible to evaluate for specific risk
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Figure 24: Unadjusted death rates per 1000 patient-years at
risk for deceased and living donor liver recipients, in the first
year after transplant, 1995–2003.
categories for 1-year posttransplant death rates in patients
who underwent a LDLT.
Age: The highest 1-year posttransplant death rates have
consistently been observed in patients who are 65 years
of age or older and in recipients less than 1 year old. No
consistent relationship was apparent between death rates
and recipient age in patients under 65 years at the time of
liver transplantation.
Race and ethnicity: With rare exceptions, African Amer-
icans have consistently had the highest 1-year posttrans-
plant death rate of any racial or ethnic group. In 2003, the
death rate observed in African Americans following a DDLT
was 222 per TPYAR compared to 164 in whites, 146 in His-
panics and 135 in Asians. It is interesting that African Amer-
icans appear to have a higher death rate both while waiting
for a liver transplant and after receiving a liver transplant.
This observation requires further evaluation.
Previous transplantation: Patients with a previous organ
transplant of any type have a markedly higher death rate
compared to patients who have only received one liver
transplant. This has been a consistent observation since
1995. In 2003, the 1-year posttransplant death rate among
DDLT recipients who had received a previous organ trans-
plant was 400 per TPYAR compared to 146 per TPYAR for
those without a previous transplant.
Primary diagnosis: During the past decade, patients who
received a DDLT for acute hepatic necrosis have almost
always had the highest death rates compared to any other
disease category. In 2003, the 1-year posttransplant death
rate observed in patients with acute hepatic necrosis was
229 per TPYAR compared to 167 per TPYAR for patients
with cirrhosis secondary to non-cholestatic liver disease,
151 for patients with malignant neoplasia, 135 for pa-
tients with cholestatic liver disease, 112 for patients with
metabolic liver disease and 87 deaths per TPYAR for pa-
tients with biliary atresia.
Disease severity: The 1-year posttransplant death rate for
patients hospitalized at the time of their DDLT has been
consistently greater over the past decade than that ob-
served for nonhospitalized patients. Patients on life sup-
port at the time of their transplant have had the lowest
posttransplant survival during the past decade. In 2003,
the death rate for patients who received their liver trans-
plant while not hospitalized was 135 per TPYAR com-
pared to 203 for hospitalized patients, 300 for patients
in an intensive care unit and 368 deaths per TPYAR for
patients on life support at the time they underwent liver
transplantation.
Patients listed as Status 1 at the time of their DDLT had
the highest death rate in 2003, at 257 deaths per TPYAR
compared to patients in any MELD score grouping. In gen-
eral, the 1-year posttransplant death rate increased with
increasing MELD score. The death rate in patients with a
MELD score of 11–20 was 133 per TPYAR compared to 179
in those patients with a MELD score of 21 to 30 and 242
deaths per TPYAR in patients with a MELD score greater
than 30. A similar trend was observed for PELD scores
in the pediatric population. However, since the number
of transplants performed in the pediatric population with
PELD values above 30 is limited, death rates for this group
could not be calculated.
Chronic hepatitis C virus infection
Chronic HCV is the single most common indication for liver
transplantation in this country and has been steadily in-
creasing over the past decade (Figure 25). In 1995, cirrhosis
secondary to chronic HCV either alone or in combination
with another cause accounted for 35% of patients under-
going liver transplantation. By 2004 this had increased to
43%. The incidence of HCC has increased over the past
decade and this appears to be primarily related to the in-
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Source: SRTR analysis, July 2005.
Figure 25: Living and deceased donor transplant recipients
with chronic HCV, 1995–2004.
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majority of patients who underwent liver transplantation
for HCC had coexistent HCV infection. In 2004, 60% of
patients with HCC who received a DDLT and 46% who
received a LDLT had chronic HCV.
Patient survival: Nearly all patients with chronic HCV de-
velop recurrent disease (16). Recurrent HCV progresses to
cirrhosis at a faster rate in liver transplant recipients com-
pared to their nontransplant counterparts and survival in
these recipients also appears to be significantly reduced
(17). It is therefore not surprising that long-term survival is
reduced in liver transplant recipients with HCV compared
to those without HCV, 68% at 5 years compared to 76%,
respectively (Figure 26).
Chronic HCV and HCC: Approximately 10% of liver trans-
plant recipients with chronic HCV between 1995 and 2004
had coexistent HCC. Since patients who undergo liver
transplantation for malignant neoplasia have the lowest
long-term survival of any group, this may contribute to the
reduced survival observed in HCV liver transplant recipi-
ents. After 3 months and 1 year, the survival of HCV recip-
ients with and without HCC was similar (Figure 27). How-
ever, by 3 and 5 years, survival in patients with coexistent
HCV and HCC declined to a greater extent than observed
in recipients with HCV alone. After 5 years, survival of pa-
tients with HCV but without HCC was 69% compared to
61% for recipients with HCV and HCC.
Chronic HCV and immunosuppression: Previous stud-
ies have suggested that certain immunosupressive agents
may contribute to more severe recurrent HCV and more
rapid progression to cirrhosis than other agents (18). Sig-
nificant controversy exists regarding these observations.
In the SRTR database, no consistent reduction in either
short-term or long-term survival was observed with respect

























Source: SRTR analysis, July 2005.
Figure 26: Unadjusted patient survival curves for deceased
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Source: SRTR analysis, July 2005. 
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Figure 27: Unadjusted patient survival of HCV positive liver
recipients at various time intervals, by HCC status.
Intestine
Transplantation of the intestine, isolated or in combination
with other abdominal organs, is an uncommon procedure,
but is being performed with increasing frequency and suc-
cess. The number of patients who received a small in-
testinal transplant has gradually increased over the past 10
years from 46 in 1995 to 152 in 2004 (Figure 29). The inci-
dence of intestinal transplantation per 1 million population
has increased from 0.18 in 1995 to 0.52 in 2004. The preva-
lence of people living with a functioning intestinal graft has
also increased. In 1995, only 65 people were alive with a
functioning intestinal graft. This value has increased step-
wise every year since; in 2004, 443 patients were alive
with a functioning intestinal graft. This increase is consis-
tent across all demographic and other patient-specific sub-
groups.
Waiting list characteristics: The number of patients ac-
tive on the waiting list at the end of the year for an intesti-
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Figure 28: Unadjusted survival of HCV positive liver recipi-
ents at various time intervals, by discharge immunosuppres-
sive regimen.
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Source: 2005 OPTN/SRTR Annual Report, Table 10.4.
Figure 29: Recipients of intestine transplants, 1995–2004.
10 years, from 69 patients in 1995 to 143 in 2004. At the
end of 2004, approximately 70% of these patients were in
the pediatric group (<18 years of age) and 14% were less
than 1 year of age. The majority of intestinal transplant
candidates (62% in 2004) suffer from short gut syndrome.
Approximately 8% of candidates active at the end of 2004
had received a previous intestinal transplant.
Time to transplant and waiting list mortality: The me-
dian time to transplant among patients on the waiting list
has decreased over time, from 497 days in 1995 to 238
days in 2004. The waiting time is longer for children and
patients with blood type O. Although the median waiting
time declined during the past 10 years, the annual death
rate per TPYAR for patients on the intestinal transplant wait-
ing list has remained fairly constant since 1995. In 1995,
the death rate for patients on the waiting list was 279 per
TPYAR compared to 306 in 2004. The waiting list death
rate appears to be highest in the youngest children and
the older adult candidates. The annual death rates in 2004
for patients under 1 year of age and between 50 and 64
years of age were 700 and 421 per TPYAR, respectively.
The lowest death rates were observed in those patients
between the ages of 6 and 17 years.
Recipient characteristics: There have been no systematic
changes in the percentage of patients transplanted over
the past 10 years by demographic characteristics (race,
ethnicity, gender, blood type, etc.). The percentage of pa-
tients who were hospitalized at the time of transplantation
has decreased from 30% in 1995 to 22% in 2004. There
has been no discernible trend in the percentage of patients
who were in the intensive care unit at the time of trans-
plant, ranging from 11% to 27% over the past decade.
Similarly, there was no trend in the number of recipients
on life support at the time of transplant, ranging from 3%
to 16% during the past 10 years.
Immunosuppression: Tacrolimus is the maintenance im-
munosuppressive agent of choice and utilized in practically
all patients who receive an intestine transplantation. This is
combined with steroids in the majority of patients. Approx-
imately 12% of patients also receive Sirolimus. Induction,
mainly with Thymoglobulin, Campath or Zenapax, is being
used with increasing frequency. Induction was only used
in 7% of recipients in 1995. This increased to 50% in 2004.
Rejection is common following intestine transplantation.
During the past decade, about half of all patients were
treated for rejection in the first year after transplantation.
Corticosteroids are utilized for treatment of rejection in
over 90% of patients. Monoclonal and polyclonal antibody
preparations have been utilized in over one-third of patients
with rejection. During 2003, the most common of these
agents were OKT3 and Campath.
Annual death rates after transplantation: The annual
death rate per 1000 patient-years at risk for recipients in
the first year after intestinal transplantation decreased by
nearly 50% between 1995 and 2003, from 417 to 208
deaths per TPYAR. There appears to be no consistent
difference in the annual 1-year posttransplant death rate
across demographic characteristics, with the possible ex-
ception of a higher death rate in children less than 1 year
of age. In 2003, among age groups that contained enough
recipients to calculate the death rate during the first post-
transplant year, children under 1 year of age had the highest
death rate at 331 deaths per TPYAR, followed by recipi-
ents 18–34 years with 313 deaths per TPYAR. The lowest
posttransplant death rate was observed in recipients aged
11–17 years with 99 deaths per TPYAR. Death rates for
intestine transplant recipients in 2003 were greatest for
patients in an intensive care unit at the time of the trans-
plant, at 628 per TPYAR compared to 218 per TPYAR for
hospitalized patients and 158 per TPYAR for patients who
were not hospitalized at the time they underwent an in-
testinal transplant.
Graft survival: Unadjusted graft survival following intesti-
nal transplantation was 87% at 3 months, 73% at 1 year,



























Source: 2005 OPTN/SRTR Annual Report, Table 10.8.
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Figure 30: Unadjusted graft survival of intestine recipients at
various time intervals following transplant.
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Source: 2005 OPTN/SRTR Annual Report, Table 10.10.
*1-Year survival not determined due to insufficient follow-up
Figure 31: Unadjusted graft survival of intestine recipients at
3 months and 1 year by year of transplant, 1995–2004.
graft survival at 3 months and 1 year has improved step-
wise since 1995 (Figure 31). Most of this improvement
has occurred since 1999. From 1995 to 1999, 3-month
graft survival ranged between 66% and 74% and 1-year
survival between 49% and 61%. Since 2000, 3-month sur-
vival increased to 88% in 2004 and 1-year survival to 77%
in 2003 (the last year for which 1-year survival is available).
Survival rates were calculated based on isolated intestinal
transplants, along with those performed in combination
with a liver and/or pancreas transplant as part of a mul-
tivisceral graft. No consistent relationship was observed
between graft survival and age, gender, race/ethnicity, re-
cipient blood type, primary diagnosis, donor age or cold
ischemia time. In contrast, graft survival was reduced in
recipients of a previous intestinal transplant and in those
hospitalized or in an intensive care unit at the time of trans-
plantation. Unadjusted graft survival at 1, 3 and 5 years for
the recipients of a primary intestinal transplant was 76%,
55% and 44%, compared to 52%, 26% and 32% in re-
cipients with a previous intestinal transplant, respectively.
Graft survival in patients who were not hospitalized at the
time of their transplant at 1, 3 and 5 years was 77%, 57%
and 48%, respectively. In comparison, graft survival in pa-
tients hospitalized at the time of their transplant was 70%,
47% and 40%, and patients in an intensive care unit had a
graft survival of 62%, 39% and 27%, respectively.
Patient survival: Adjusted patient survival for the recip-
ients of an intestine transplant was 90% at 3 months,
80% at 1 year, 61% at 3 years and 52% after 5 years (Fig-
ure 32). As was observed for graft survival, unadjusted pa-
tient survival at 3 months and 1 year remained relatively sta-
ble between 1995 and 1999 and then increased stepwise
through 2004. Between 1995 and 1999, 3-month survival
ranged between 77% and 81% (Figure 33). This increased
to 90% in 2004. Between 1995 and 1999, patient survival
at 1 year ranged between 57% and 68%. This increased
to 81% in 2003 (the last year for which 1-year survival
data is available). As with graft survival, patient survival




























Source: 2005 OPTN/SRTR Annual Report, Table 10.11.
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Figure 32: Adjusted patient survival at various time intervals
following intestine transplant.
and those performed in combination with a liver and/or pan-
creas transplant as part of a multivisceral graft. No notable
difference in survival following intestinal transplant was ob-
served with respect to recipient age, gender, race/ethnicity,
recipient blood type, primary diagnosis, donor age or cold
ischemia time.
As was observed with graft survival, the intensity of med-
ical therapy, assessed by the need for hospitalization or
an intensive care unit, had a negative impact on patient
survival. Unadjusted patient survival at 1, 3 and 5 years for
patients not hospitalized at the time of transplant was 82%,
67% and 58%, respectively. For hospitalized patients, pa-
tient survival was 76%, 50% and 46% and for those in an
intensive care unit survival had declined to 68%, 42% and
33%, respectively.
Intestinal transplants by transplant center: Between
1995 and 1998 only three centers had performed five or
more intestinal transplants each year. In contrast, during
2004 the number of centers that performed five or more
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Source: 2005 OPTN/SRTR Annual Report, Table 10.13.
*1-Year survival not determined due to insufficient follow-up
Figure 33: Unadjusted patient survival of intestine recipients
at various time intervals, by year of transplant, 1995–2004.
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the total number of centers performing intestinal transplan-
tation in the United States is relatively small, a growing
number of centers are gaining experience and developing
expertise in this procedure.
Summary
The overall success of liver transplantation continues to im-
prove. The increased utilization of deceased donor livers
and a resurgence in living donor transplants has enabled
the number of liver transplants performed yearly to sur-
pass 5500. This represents a 51% increase in the number
of liver transplants performed yearly since 1995. Although
waiting time for all patients on the waiting list has not de-
clined, pretransplant death rates have. Three years after
implementation of the MELD/PELD system, the percent-
age of patients undergoing liver transplantation with higher
MELD/PELD scores has increased and the percentage of
recipients with HCC or exceptions for reasons other than
HCC has remained relatively stable. Posttransplant death
rates have also declined during the past decade.
There is now mounting evidence that donor age impacts
posttransplant graft and patient survival. Specifically, utiliz-
ing livers from donors over 50 years of age is associated
with a significant decline in long-term survival. Why short-
term survival appears to be only marginally affected by the
older donor remains to be explained.
Chronic HCV remains the single most common indica-
tion for liver transplantation and has become even more
prevalent during the past decade. In 2004, 43% of all
liver transplants were in patients with chronic HCV. Long-
term survival following liver transplantation does appear
to be reduced in patients with chronic HCV. Patients with
HCV and coexistent HCC have even lower survival com-
pared to patients with HCV alone. Neither of the standard
maintenance immunosuppression regimens, cyclosporin
or tacrolimus with or without MMF, appears to affect long-
term graft or patient survival.
Intestinal transplantation is being performed at more cen-
ters, with increasing frequency and success. Posttrans-
plant graft survival has increased stepwise since 2000 and
patient survival at 1 year now exceeds 80% for the first
time.
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